No Result
View All Result
SUBSCRIBE | NO FEES, NO PAYWALLS
MANAGE MY SUBSCRIPTION
NEWSLETTER
Corporate Compliance Insights
  • Home
  • About
    • About CCI
    • CCI Magazine
    • Writing for CCI
    • Career Connection
    • NEW: CCI Press – Book Publishing
    • Advertise With Us
  • Explore Topics
    • See All Articles
    • Compliance
    • Ethics
    • Risk
    • FCPA
    • Governance
    • Fraud
    • Internal Audit
    • HR Compliance
    • Cybersecurity
    • Data Privacy
    • Financial Services
    • Well-Being at Work
    • Leadership and Career
    • Opinion
  • Vendor News
  • Library
    • Download Whitepapers & Reports
    • Download eBooks
    • New: Living Your Best Compliance Life by Mary Shirley
    • New: Ethics and Compliance for Humans by Adam Balfour
    • 2021: Raise Your Game, Not Your Voice by Lentini-Walker & Tschida
    • CCI Press & Compliance Bookshelf
  • Podcasts
    • Great Women in Compliance
    • Unless: The Podcast (Hemma Lomax)
  • Research
  • Webinars
  • Events
  • Subscribe
Jump to a Section
  • At the Office
    • Ethics
    • HR Compliance
    • Leadership & Career
    • Well-Being at Work
  • Compliance & Risk
    • Compliance
    • FCPA
    • Fraud
    • Risk
  • Finserv & Audit
    • Financial Services
    • Internal Audit
  • Governance
    • ESG
    • Getting Governance Right
  • Infosec
    • Cybersecurity
    • Data Privacy
  • Opinion
    • Adam Balfour
    • Jim DeLoach
    • Mary Shirley
    • Yan Tougas
No Result
View All Result
Corporate Compliance Insights
Home Compliance

Where in the World Is Joe’s Blood?

Tomorrow’s sophisticated cell therapy treatments rely on tackling supply chain woes today

by Joe Slota
June 29, 2022
in Compliance
gene therapy supply chain abstract concept

Cell and gene therapy is revolutionizing healthcare. But its efficacy relies on good old-fashioned supply chain management. Good luck with that.

Take a seat, Joe. We’re going to draw a vial of your blood and ship it to the lab for gene splicing. We expect to have it back here in the office in exactly seven days and we’ll re-inject it then. That should cure your cancer.

That fantastic scenario is still way off in the future, but a variation of it is within sight. With recent developments of sophisticated gene-editing tools like CRISPR, scientists are getting closer to treating life-threatening diseases like cancer, diabetes and sickle cell anemia through cell and gene therapies that correct flaws in our DNA.

It’s precision medicine at work — innovative treatment tailored specifically to the genetic characteristics of the individual. We can expect these miracles to be delivered economically and quickly.

That is, if the providers get the right product into the right arms. For all the wonder of cell and gene therapy, the question about its efficacy hangs on something seemingly mundane, yet extremely critical: the end-to-end supply chain.

Handle with care

As anyone who has confronted the empty store shelves so prevalent since the pandemic can attest, an efficient and reliable supply chain is vital for meeting customer demand.

It’s even more important when you’re talking about people’s lives.

Precision medicine demands just that: precision. It demands expert knowledge and careful handling of vulnerable genetic material at every step in a circular process that starts and ends with Joe. That requires people — from the carriers overseeing the controlled containers, the technicians handling Joe’s cells, the return of what is now a drug product to the carriers and those back at the medical center waiting to reinject Joe. And, of course, there’s Joe himself.

Precision and visibility are crucial for making sure Joe’s blood cells are handled by the strict dictates of his treatment protocol. Speed is of the essence; maintaining and preserving the “contents” throughout and delivering them expediently with the guarantee that no one else’s genetic material has “infected” the product is paramount.

Clearly, it’s not your grandparents’ supply chain. You can’t scale up by hiring more drivers, renting more warehouses or throwing another box of widgets on the pallet. Problem with the product? There’s no label you can print out for returns. This supply chain, or circle, is literally a life-and-death operation and not every company in the precision medical field is ready.

As this bold new world dawns and more businesses rush to enter the market, the question then becomes: What do all parties along the supply chain need to know? And do they even know what they don’t know?

The chain of identity

The answers begin with understanding the concept of chain of identity (COI), the process on which all other elements in the precision medicine supply circle depend. Get it right and probably no one will notice. Get it wrong? You can kiss Joe goodbye.

COI requires mapping Joe’s treatment protocol at every step to ensure integrity, from blood draw to re-injection. You’ve got to identify the key people involved (e.g., stakeholders, critical third parties, CMOs) and monitor how information flows among them. And though you might be aware of the high-level steps involved with the process, you can’t lose sight of the lower-level steps unique to Joe’s treatment and those driven by the type of therapy in question.

Every treatment is one-of-a-kind. Cells can come from various areas of the body and be drawn in different ways, making the steps and people involved just as diverse. That differentiation means less consistency in the process and more room for error. No one wants this high-level operation to fail because an individual misses a small step or enters data about the recipient’s bone marrow incorrectly.

Identify your COI capabilities

To establish a precisely functioning COI, it helps to look at a tiered hierarchy of capabilities in the supply chain process separated into primary, secondary and non-essentials. From there, companies can evaluate where they stand in their ability to maintain the chain. They can rank capabilities that drive core functions and relegate others as “nice-to-have” for the moment.

As organizations establish the COI as a critical component of operations, the key to success is to focus on the capabilities that truly drive patient outcomes. Secondary objectives are irrelevant.

After reviewing capabilities, the gaps in your COI should become apparent. Filling them is essential in a booming, rapidly evolving field where opportunities to expand are myriad. You may in fact already have advantages over the competition, but the future is coming on so fast that today’s cutting-edge business can quickly become last year’s model in a heartbeat.

That phenomenon makes it important to identify partners who not only understand this complex field but who are embedded in it. To make the most of an investment and reduce the risk of failure, you want to avoid the growing pains that newcomers often experience.

Denice Torres, a board member for several biopharma companies, stresses the need for partnering in the gene and cell therapy industry to unlock its promises. 

“Realizing ideas requires investment, and to an increasing extent, partnerships and collaboration to ensure scale, reduce risk, and harness new technologies,” she says. “The ability to effectively collaborate will become a growing source of competitive advantage.”

Pick your partners

The key, then, is to find partners experienced in precision medicine who understand COI and know how to prioritize capabilities. You want partners who can train people, put them in place and provide a solution-oriented approach that can quickly handle widely changing variables and eliminate — not just mitigate — risk.

The ability to communicate changes to everyone in the COI promptly, including third and, in some cases, fourth parties is a high priority. Products have to get out in the market promptly and within reasonable budgets. Your partner can help you get your COI buttoned down, and then assist with planning your end-to-end supply chain circle.

It’s no exaggeration to say that Joe’s life depends on nimbleness and adaptability. You don’t want to put him at further risk just because the number of cells collected from Joe was not what you anticipated needing at the start or the drug product you received back was insufficient.

It’s about the people

Your partner must ensure that your COI solutions and processes are designed with everyone on the chain in mind, including the most important party, Joe himself. Training is an absolute must. That requires keeping people up-to-date with protocols and changing products, how to incorporate these processes into what they are already doing so you don’t make their jobs harder, accounting for changing personnel, etc. Flexibility is key.

Ready for delivery

COI has become part of the everyday vernacular in the precision medicine field, with companies working in cell and gene therapy truly needing to be able to grasp the complexities of implementing COI capabilities into their supply chains. By integrating the above processes, companies will be able to drive bottom-line growth. Most importantly, they’ll know where in the world Joe’s blood is every step of the way.

 

This article originally appeared in FTI Consulting Journal and is published here with permission. 

 


Tags: Supply Chain
Previous Post

Diving Into the Deep End of ESG Reporting? Do You Even Know How to Get to the Pool?

Next Post

Survey: Leaders Claim to Be Ready for State Privacy Laws; Few Actually Are.

Joe Slota

Joe Slota

Joe Slota is a senior managing director at FTI Consulting. He has more than 40 years of experience in the life sciences industry.

Related Posts

supply chain shipping containers

‘You Don’t Want to Be the First Company to Not Comply’: How Trump’s Tariffs Are Shaking Supply Chains

by Cathy Siegner
March 31, 2025

The ripple effects of tariff policies extend far beyond simple cost increases, creating complex compliance challenges that span legal, financial...

news roundup header image papers

Internal Audit Group Prepares New Third-Party Topical Requirement

by Staff and Wire Reports
March 7, 2025

Most organizations expect to increase fraud budgets

mineral mining operation

Why Critical Minerals Demand a Compliance Revolution

by Rebeca Vergara Gaona
February 11, 2025

Corporate compliance lessons could help strengthen intergovernmental mineral agreements before problems arise

news roundup bundled papers

Audit Leaders Struggle to Keep Pace With AI Demands

by Staff and Wire Reports
January 31, 2025

‘Forever chemicals’ present in most manufacturing supply chains; global political shifts poised to upend corruption enforcement

Next Post
snooping on private data

Survey: Leaders Claim to Be Ready for State Privacy Laws; Few Actually Are.

No Result
View All Result

Privacy Policy | AI Policy

Founded in 2010, CCI is the web’s premier global independent news source for compliance, ethics, risk and information security. 

Got a news tip? Get in touch. Want a weekly round-up in your inbox? Sign up for free. No subscription fees, no paywalls. 

Follow Us

Browse Topics:

  • CCI Press
  • Compliance
  • Compliance Podcasts
  • Cybersecurity
  • Data Privacy
  • eBooks Published by CCI
  • Ethics
  • FCPA
  • Featured
  • Financial Services
  • Fraud
  • Governance
  • GRC Vendor News
  • HR Compliance
  • Internal Audit
  • Leadership and Career
  • On Demand Webinars
  • Opinion
  • Research
  • Resource Library
  • Risk
  • Uncategorized
  • Videos
  • Webinars
  • Well-Being
  • Whitepapers

© 2025 Corporate Compliance Insights

Welcome to CCI. This site uses cookies. Please click OK to accept. Privacy Policy
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT
No Result
View All Result
  • Home
  • About
    • About CCI
    • CCI Magazine
    • Writing for CCI
    • Career Connection
    • NEW: CCI Press – Book Publishing
    • Advertise With Us
  • Explore Topics
    • See All Articles
    • Compliance
    • Ethics
    • Risk
    • FCPA
    • Governance
    • Fraud
    • Internal Audit
    • HR Compliance
    • Cybersecurity
    • Data Privacy
    • Financial Services
    • Well-Being at Work
    • Leadership and Career
    • Opinion
  • Vendor News
  • Library
    • Download Whitepapers & Reports
    • Download eBooks
    • New: Living Your Best Compliance Life by Mary Shirley
    • New: Ethics and Compliance for Humans by Adam Balfour
    • 2021: Raise Your Game, Not Your Voice by Lentini-Walker & Tschida
    • CCI Press & Compliance Bookshelf
  • Podcasts
    • Great Women in Compliance
    • Unless: The Podcast (Hemma Lomax)
  • Research
  • Webinars
  • Events
  • Subscribe

© 2025 Corporate Compliance Insights